Browse the evidence

Replacing saturated fatty acids (SFA) from dairy foods with polyunsaturated fatty acids (PUFA) reduces LDL cholesterol but does not consistently reduce cardiovascular disease (CVD) risk or mortality, suggesting that LDL-C reduction alone is not a reliable predictor of CVD outcomes when the source is dairy.

Current guidelines suggest limiting saturated fats to reduce heart disease risk. However, this review indicates that replacing dairy saturated fats with polyunsaturated fats lowers LDL cholesterol but does not necessarily lower your actual risk of heart attacks or death. This suggests that simply counting saturated fat grams may be less important than the overall food matrix (e.g., eating whole dairy products) and other lipid markers like the LDL particle size.

High intake of saturated fatty acids from dairy foods is associated with neutral or negative (protective) associations with cardiovascular disease risk, unlike SFAs from other sources which may increase risk.

You do not need to restrict dairy foods to manage heart health risk. While general guidelines limit saturated fats, evidence suggests that the specific fats found in dairy (like C15:0 and C17:0) are associated with neutral or even protective effects on cardiovascular disease, unlike saturated fats from other sources.

Semaglutide administration significantly reduces the incidence of atrial fibrillation by 42% compared to placebo in patients at high cardiovascular risk, primarily those with type 2 diabetes or obesity.

If you have type 2 diabetes or are overweight with high heart disease risk, ask your doctor about semaglutide. This medication has been shown to significantly lower your chance of developing atrial fibrillation, a common heart rhythm problem, regardless of whether you take it as a pill or a weekly injection. This benefit exists even if you do not have diabetes.

Behavioral weight management programs (BWMPs) produce sustained improvements in cardiometabolic risk factors (blood pressure, lipid profile, glycemic control) for at least 5 years after program end, despite significant weight regain.

If you participate in a structured weight loss program, expect your blood pressure, cholesterol, and blood sugar to improve significantly. Even if you regain some weight after the program ends, these health benefits will likely persist for at least five years. Do not be discouraged by partial weight regain; the metabolic improvements are durable.

Short-term consumption of fast-food meals (a subset of UPFs) increases bile-tolerant bacteria (Collinsella, Parabacteroides, Bilophila) and decreases fiber-fermenting bacteria (Lachnospiraceae, Butyricicoccus).

Eating fast food for just 4 days can shift your gut bacteria, increasing bile-tolerant types and decreasing fiber-fermenting types. To maintain a healthy microbiome, limit fast food frequency and prioritize fiber-rich foods.

Weight cycling (yo-yo dieting) is associated with increased cardiovascular risk and morbidity, whereas sustained weight loss or maintenance reduces risk.

Avoid yo-yo dieting. Repeatedly losing and regaining weight increases your risk of heart disease. Focus on sustainable weight loss or maintenance. If you struggle with weight cycling, seek professional help to establish stable habits.

GLP-1 receptor agonists (Liraglutide, Semaglutide, Tirzepatide) are effective for chronic weight management in obese patients, but improper use without clinical indication can lead to serious side effects.

GLP-1 drugs like Semaglutide and Tirzepatide are effective for weight loss in obese patients with comorbidities. However, they are prescription medications with serious side effects. Do not use them without medical indication or supervision. Follow your doctor's dosage and monitoring plan.

Excess caloric intake, particularly from carbohydrates (fructose/glucose) and saturated fats, drives de novo lipogenesis and hepatic fat accumulation, whereas unsaturated fats (omega-3) may reduce liver fat.

Focus on reducing added sugars (especially fructose/sweetened beverages) and saturated fats. Replace them with unsaturated fats (like omega-3s) and whole food carbohydrates. Total calories matter, but what you eat matters more for your liver.

Tirzepatide treatment (5-15 mg once weekly) significantly improves health-related quality of life (HRQoL), including physical function and psychosocial well-being, compared to placebo in adults with obesity or overweight.

If you have obesity or overweight, treatment with tirzepatide (5-15 mg once weekly) along with lifestyle changes significantly improves your quality of life, physical function, and mental well-being compared to placebo. The greater the weight loss achieved (especially ≥5%), the greater the improvement in how you feel and function daily.

Greater degrees of weight reduction achieved with tirzepatide are associated with greater improvements in health-related quality of life (HRQoL), particularly when weight loss is ≥5%.

With tirzepatide, you don't need to lose a massive amount of weight to see benefits. Losing 5% or more of your body weight is associated with noticeable improvements in how you feel and function, with greater losses leading to even better outcomes.

Caloric restriction triggers adaptive thermogenesis, including reduced BMR/RMR, hormonal shifts (lowered T3, leptin, increased ghrelin), and increased appetite, which persist long-term and contribute to weight regain.

When you restrict calories, your body fights back by lowering your metabolic rate and increasing hunger hormones. This is a survival mechanism, not a personal failing. To manage this, consider strategies that preserve muscle mass, manage stress, and perhaps use precision nutrition to mitigate these adaptive responses.

Sustained lockdown-induced sedentary behavior and dietary shifts in healthy adults cause significant worsening of cardiovascular risk factors, including increased BMI, body fat, LDL cholesterol, blood glucose, and blood pressure.

Maintain physical activity and monitor dietary intake during periods of restricted movement. The study shows that even healthy adults experience measurable declines in metabolic health (weight, lipids, glucose) when sedentary, highlighting the need for proactive lifestyle management during lockdowns or similar restrictions.

Cotadutide, a dual GLP-1 and glucagon receptor agonist, significantly reduces urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and chronic kidney disease compared to placebo, with effects sustained over 26 weeks.

If you have type 2 diabetes and early kidney disease, cotadutide (a daily injection) significantly reduces albumin in your urine, a key marker of kidney health. This effect is seen at higher doses (300-600 mg) and is sustained over time. It works on top of your current medications. While it causes some GI side effects, these are generally manageable and similar to other GLP-1 drugs. Discuss with your doctor if this dual-agonist approach is right for you, especially if you are not getting enough kidney protection from current treatments.

Obesity is an independent risk factor for the onset and progression of chronic kidney disease (CKD), with visceral adiposity and fatty kidney disease serving as key pathophysiological mediators.

Maintaining a healthy weight is critical for kidney health. Excess visceral fat directly harms kidney function through inflammation and blood pressure changes. Weight management is a primary strategy to prevent or slow kidney disease.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and reduce albuminuria, offering potential kidney protection, though their direct impact on eGFR decline in normal-functioning kidneys is not yet fully established.

GLP-1 medications like semaglutide help with weight loss and have been shown to reduce albuminuria (a sign of kidney stress). They are a promising option for kidney protection, especially for those with diabetes and obesity.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) improve liver histology in MASH patients, with semaglutide demonstrating the strongest evidence for resolving steatohepatitis without worsening fibrosis.

If you have MASH, GLP-1 medications like semaglutide are currently the most evidence-backed pharmacological option to improve liver health, potentially resolving the disease without worsening scarring. This is particularly relevant if you also have Type 2 Diabetes or obesity, as these drugs address the underlying metabolic drivers. While weight loss contributes, the histological benefits appear to extend beyond weight reduction alone.

Liraglutide (1.8 mg) improves liver enzymes and reduces hepatic steatosis in MASH patients, though its ability to resolve NASH histology is modest compared to semaglutide.

Liraglutide 1.8 mg can significantly lower liver enzymes (ALT/AST) and reduce liver fat in MASH patients. However, it is less effective than semaglutide at fully resolving the inflammation (NASH) itself, so it may be a good option for enzyme control but less so for complete histological reversal.

Consuming a higher variety of protein sources (from 8 major food groups) at their respective appropriate quantity windows is inversely associated with the risk of new-onset hypertension.

To lower your risk of high blood pressure, focus on eating a wide variety of protein sources—such as grains, red meat, poultry, fish, eggs, and legumes—rather than just increasing total protein. Ensure you are eating these sources in moderate, balanced amounts, as both too little and too much of specific types can increase risk. Aim for a diverse diet that includes small portions from each of these major protein groups.

There is no single 'appropriate' amount for all protein sources; each source (red meat, poultry, fish, etc.) has a unique non-linear relationship with hypertension risk, requiring source-specific quantity windows.

Don't just focus on hitting a total protein number. Pay attention to what kind of protein you are eating. Some sources like red meat and poultry may increase risk if eaten in excess, while others like legumes and eggs may offer protection. A balanced mix of moderate amounts from various sources is key.

Very low-calorie diets (VLCD) are suitable for short-term use in specific clinical populations, such as those with Type 2 Diabetes (T2D), to improve glycemic control and cardiovascular risk factors, but are not recommended for long-term use or for older adults at risk of sarcopenia.

If you have Type 2 Diabetes, a very low-calorie diet might help your blood sugar and weight quickly, but only under doctor supervision and for a short time. Do not use this if you are older and worried about muscle loss.

GLP-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk and body weight in obese patients with pre-existing cardiovascular disease, regardless of diabetes status, by modulating metabolic pathways, reducing inflammation, and slowing gastric emptying.

If you are overweight or obese and have existing heart disease, GLP-1 receptor agonists like semaglutide are a proven treatment to lower your risk of heart attacks, strokes, and death from heart causes, even if you don't have diabetes. These drugs work by mimicking a hormone that helps control blood sugar, reduces appetite, and slows digestion. While they are injections, their ability to protect your heart and reduce weight makes them a critical tool for secondary prevention. Always discuss with your doctor if this is right for you, especially regarding side effects and dosing.

Obesity pharmacotherapies, specifically high-dose semaglutide and tirzepatide, are highly effective for long-term weight management (>10% loss at 6 months) but remain dramatically underprescribed due to clinician knowledge gaps, safety concerns, and insurance coverage limitations.

If you qualify for obesity pharmacotherapy, discuss semaglutide or tirzepatide with your provider. While highly effective (>10% weight loss), access is limited by insurance. Ask about coverage options, especially if you have cardiovascular risk, as recent policy changes may improve access.

Overreliance on BMI as the sole metric for obesity management hinders clinical implementation and confuses clinicians, leading to suboptimal care; waist circumference is a more useful tool for assessing health risk.

Ask your clinician to measure your waist circumference, not just your BMI. This provides better insight into your cardiovascular risk and helps prioritize obesity management interventions.

Physical activity improves metabolic health and reduces blood glucose levels independently of weight loss and insulin signaling pathways.

You do not need to lose weight to get the metabolic benefits of exercise. Even if your weight stays the same, physical activity helps your muscles take up glucose without relying on insulin, which is crucial for preventing or managing type 2 diabetes and metabolic syndrome. Focus on consistency rather than just the number on the scale.